🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Leicester
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Leicester

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2005 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 417
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca17 Merck Sharp & Dohme LLC15 Hoffmann-La Roche14 Sanofi9 Boehringer Ingelheim8
Site city
London2005 Manchester672 Birmingham470 Glasgow437 Cambridge417
All 425 cities
Target enrolment
to
206 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
NCT05990738Small Cell Lung Carcinoma (SCLC)
Boehringer Ingelheim
Phase 1
69
Leicester
2024-02-14
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
Boehringer Ingelheim
Phase 3
428
Edinburgh, Leicester, London, Sutton
2024-02-09
By invitation
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315Wheezing, Asthma
Sanofi
Phase 3
90
Birmingham, Leicester, London, Bradford
2024-01-03
Active, closed
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)
NCT06111586Type 1 Diabetes Mellitus
Sanofi
Phase 2
197
Cambridge, Dundee, Birmingham, Glasgow, Leicester, Harrow
2023-12-11
Active, closed
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471NonSegmental Vitiligo
Incyte Corporation
Phase 3
450
Ipswich, Leicester, London, Nottingham, Walsall
2023-11-27
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06031441Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
Genentech, Inc.
Phase 1
65
Cambridge, Leicester, London, Oxford, Sutton
2023-11-27
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
AstraZeneca
Phase 3
625
Cardiff, Chelsea, Leicester, Liverpool, London, Oxford, Surrey, Sutton
2023-11-23
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
Olema Pharmaceuticals, Inc.
Phase 3
510
Leicester, Nottingham, Taunton, Bodelwyddan, London
2023-11-16
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
AstraZeneca
Phase 3
863
Cambridge, Leeds, Leicester, London, Manchester, Newcastle upon Tyne, Portsmouth, Taunton
2023-11-09
Active, closed
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
NCT06055725Spasticity as Sequela of Stroke
Ipsen
Observational
1,057
Leicester, Liverpool, London, Middlesbrough, Nottingham
2023-11-01
Recruiting
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
NCT06725758Solid Tumours
Orion Corporation, Orion Pharma
Phase 1/2
315
Leicester, London, Sheffield
2023-10-26
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim
Phase 2
204
Leicester, London, Manchester, Newcastle upon Tyne
2023-10-13
Active, closed
Enlighten Study: The EV-ICD Post Approval Registry
NCT06048731Ventricular Arrhythmia, Tachycardia
Medtronic
Observational
1,000
Leicester, London
2023-09-01
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
AstraZeneca
Phase 3
231
Birmingham, Bradford, Bristol, Glasgow, Leicester, London, Nottingham, Stoke-on-Trent
2023-08-24
Active, closed
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610Primary IgA Nephropathy
Hoffmann-La Roche
Phase 3
459
Cambridge, Leicester, London, Oxford, Salford
2023-08-08
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
383
Bristol, Brighton, Salford, Leicester, London, Nottingham
2023-07-06
Active, closed
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510Non Small Cell Lung Cancer
OncoC4, Inc.
Phase 3
630
Birmingham, Cambridge, Exeter, Leicester, London, Middlesbrough, Torquay, Manchester
2023-06-28
Active, closed
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576Lupus Erythematosus, Systemic
Viatris Innovation GmbH
Phase 3
451
Leicester, London
2023-06-26
Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
NCT05714839Multiple Myeloma
GlaxoSmithKline
Phase 1/2
123
Leicester, Oxford, Plymouth
2023-06-14
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
NCT05753501Hematologic Cancer
AbbVie
Phase 1
135
Cambridge, Leicester, London
2023-06-09
Active, closed
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Alexion Pharmaceuticals, Inc.
Phase 3
165
Leicester, Norwich, Oxford
2023-06-07
Recruiting
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
NCT05862285Cancer
Hoffmann-La Roche
Phase 3
100
Leicester, Surrey
2023-06-01
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
NCT05800665Advanced Prostate Cancer, Metastatic Prostate Cancer
Genentech, Inc.
Phase 1
210
Cambridge, Leicester, Manchester, Sutton
2023-05-02
Active, closed
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT05609968Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 3
614
Leicester, London, Metropolitan Borough of Wirral
2023-02-06
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
213
Leeds, Leicester, Surrey, Wolverhampton
2022-12-15
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
AstraZeneca
Phase 3
3,527
Bristol, Dundee, Glasgow, Hampshire, Huddersfield, Leeds, Leicester, London
2022-12-13
Recruiting
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428Carcinoma, Non-small-Cell Lung
Janssen Research & Development, LLC
Phase 2
520
Cheltenham, Devon, Edinburgh, Leicester, London, Nottingham, Portsmouth
2022-11-11
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020Multiple Myeloma
Pfizer
Phase 3
1,116
Leicester, Edinburgh, Oxford, Stoke-on-Trent, Cardiff, Glasgow
2022-11-10
Recruiting
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2
260
Manchester, Leicester, Liverpool, Oxford, London
2022-10-18
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085Relapsed or Refractory Multiple Myeloma
Celgene
Phase 3
810
Cambridge, Truro, Airdrie, London, Leicester, Barnet, Newcastle upon Tyne, Stoke-on-Trent
2022-09-20
Recruiting
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT05334368Hypereosinophilic Syndrome
GlaxoSmithKline
Phase 3
109
Leicester
2022-09-06
Recruiting
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms
Stemline Therapeutics, Inc.
Phase 1/2
73
Leicester, Liverpool, London, Manchester
2022-08-31
Active, closed
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578Dermatitis Atopic
Sanofi
Phase 2/3
1,856
Bristol, London, Glasgow, Portsmouth, Leicester, Nottingham, Liverpool
2022-08-22
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
Novartis Pharmaceuticals
Phase 2
240
Cambridge, Leicester
2022-08-10
Recruiting
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
NCT05463263Lymphoma, B-Cell, Lymphoma, T-Cell
Step Pharma, SAS
Phase 1/2
180
Leicester, London, Manchester, Nottingham, Oxford, Plymouth, Sutton
2022-08-03
Active, closed
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584Type 2 Diabetes
Eli Lilly and Company
Phase 4
780
Aberdeen, Dundee, Ely, Plymouth, Hull, Leicester, Rotherham
2022-08-01
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
737
Bristol, Leicester, London, Swansea
2022-07-22
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Daiichi Sankyo
Phase 3
586
Birmingham, Glasgow, Leeds, Leicester, London, Manchester, Wolverhampton
2022-07-08
Active, closed
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
NCT05405166Plasma Cell Myeloma Recurrent
Sanofi
Phase 3
531
Derby, Birmingham, Leicester, London, Norwich
2022-06-23
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
Dimerix Bioscience Pty Ltd
Phase 3
286
Birmingham, Bristol, Canterbury, Carshalton, Coventry, Glasgow, Leicester, London
2022-05-30
Active, closed
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810Non Small Cell Lung Cancer, KRAS Activating Mutation
Verastem, Inc.
Phase 1/2
153
Leicester, London, Sutton
2022-04-12
By invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Leicester, London
2022-04-05
Recruiting
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
NCT05312879Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated
Phase 2/3
466
Basildon, Bellshill, Birmingham, Carshalton, Leicester, London, Manchester, Nottingham
2022-03-30
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Cambridge, Gloucester, Leicester, London, Salford, Swansea
2022-03-15
Active, closed
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973Amyloidosis
Janssen Research & Development, LLC
Phase 2
151
Leicester, London
2022-03-01
Recruiting
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
NCT05102019Refractory Angina
Shockwave Medical, Inc.
Not applicable
380
Basildon, Birmingham, Bristol, Cambridge, Dorchester, Kettering, Leicester, Liverpool
2022-01-04
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
Merck Sharp & Dohme LLC
Phase 3
643
East Sussex, Cambridge, Truro, Kendal, Dundee, Leicester, London, Cardiff
2021-12-13
Active, closed
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567Small-Cell Lung Cancer
Hoffmann-La Roche
Phase 3
660
Blackpool, GB Manchester, Hull, Leeds, Leicester, London
2021-11-18
Active, closed
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734Non-Small Cell Lung Cancer
Gilead Sciences
Phase 3
603
Birmingham, Colchester, Glasgow, Leeds, Leicester, London, Manchester
2021-11-17
Active, closed
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090Papillary Renal Cell Carcinoma
AstraZeneca
Phase 3
148
Leicester, London
2021-10-28
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
Novartis Pharmaceuticals
Phase 3
448
Newcastle upon Tyne, Cambridge, Leicester, London, Salford
2021-09-20
Active, closed
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
600
Birmingham, Leeds, Leicester, London, Oxford, Plymouth
2021-09-20
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
Hoffmann-La Roche
Phase 3
4,170
Leicester, London, Nottingham, Preston
2021-08-27
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
342
Truro, Leicester, London, Manchester, Blackpool, Londonderry
2021-06-18
Active, closed
The SELUTION DeNovo Study
NCT04859985Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
3,326
Stoke-on-Trent, Bournemouth, Brighton, Bristol, Edinburgh, Glasgow, Leicester, Manchester
2021-05-15
Recruiting
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis
AgNovos Healthcare, LLC
Not applicable
2,400
Birmingham, Leicester, Edinburgh, Glasgow, Manchester, Nottingham
2021-04-24
Active, closed
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma
Incyte Corporation
Phase 3
654
Birmingham, Bristol, Leicester, London, Manchester, Middlesbrough, Sutton, Wolverhampton
2021-04-15
Active, closed
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Mirati Therapeutics Inc.
Phase 3
453
Birmingham, Edinburgh, Glasgow, Leicester, Manchester
2021-02-23
Recruiting
An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias
NCT04750798Arrhythmias, Cardiac
Biosense Webster, Inc.
Observational
8,000
Leicester, London
2021-02-22
Active, closed
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
NCT04776434Peripheral Artery Disease
M.A. Med Alliance S.A.
Not applicable
723
Frimley, Leicester, London, Redhill
2021-02-08
Active, closed
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
NCT04624659Sickle Cell Disease
Forma Therapeutics, Inc.
Phase 3
450
Leicester, London, Oxford, Sheffield
2021-01-29
Recruiting
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
NCT04752826Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
BioInvent International AB
Phase 1/2
250
Birmingham, Leicester, London, Manchester, Southampton
2021-01-25
Recruiting
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242Pediatric Migraine
Pfizer
Phase 3
2,100
Leicester, London
2021-01-15
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
990
Bristol, Cottingham, Glasgow, London, Sutton, Leicester, Manchester
2021-01-10
Active, closed
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
NCT04626518Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 1/2
370
Southampton, Glasgow, Preston, Leicester, London, Edinburgh, Cardiff, Manchester
2020-12-17
Active, closed
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
NCT04626479Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 1/2
400
Southampton, Glasgow, Preston, Leicester, London, Edinburgh, Cardiff, Manchester
2020-12-16
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
404
Bristol, Hertford, Leicester, London, Salford
2020-12-11
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.
Phase 2/3
626
Birmingham, Edinburgh, Kent, Leicester, London, Manchester, Surrey
2020-12-02
Active, closed
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
NCT04592913Gastrointestinal Neoplasms, Esophagogastric Junction
AstraZeneca
Phase 3
957
Cambridge, Dundee, Glasgow, Leicester, London, Manchester, Oxford, Surrey
2020-11-17
Active, closed
CHAMPION-AF Clinical Trial
NCT04394546Atrial Fibrillation, Stroke, Bleeding
Boston Scientific Corporation
Not applicable
3,000
Brighton, Leicester, Oxford
2020-10-15
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
992
Brighton, Leicester, London, Maidstone, Peterborough, Plymouth, Sutton, Truro
2020-10-09
Active, closed
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
NCT04270409Plasma Cell Myeloma
Sanofi
Phase 3
337
Bournemouth, London, Leicester, Southampton
2020-06-16
Active, closed
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
NCT04214288Advanced ER-Positive HER2-Negative Breast Cancer
AstraZeneca
Phase 2
240
Derby, Leicester
2020-04-22
Active, closed
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT04129502Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Takeda
Phase 3
354
London, Sutton, Bebington, Leicester, Manchester
2020-01-10
Active, closed
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
NCT04091126Multiple Myeloma
GlaxoSmithKline
Phase 1
118
Leicester, Oxford, Southampton
2019-12-18
Active, closed
First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients (FUTURE-HF)
NCT04203576Heart Failure
Foundry Innovation & Research 1, Limited (FIRE1)
Not applicable
50
Bournemouth, Glasgow, Leicester, London, Portsmouth, Southampton
2019-11-22
Active, closed
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
NCT04157348Eosinophilic Granulomatous Vasculitis
AstraZeneca
Phase 3
140
Cambridge, Leicester, London, Portsmouth
2019-10-29
Active, closed
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
NCT03953300Asthma
AstraZeneca
Phase 4
75
Cambridge, Headington, Leicester, Liverpool, London, Wythenshawe
2019-10-08
Active, closed
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
NCT04083339Diabetic Cardiomyopathies
Applied Therapeutics, Inc.
Phase 3
675
Dundee, Glasgow, Leicester, London, Manchester
2019-09-20
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
Novartis Pharmaceuticals
Phase 1/2
300
Bath, Leicester, London, Manchester, Oxford, Southampton, Sutton, Taunton
2019-09-18
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
AbbVie
Phase 3
165
Plymouth, Leicester, London, Southampton, Blackpool, Liverpool, Wolverhampton
2019-09-06
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT04077723Lymphoma, Non-Hodgkin
Hoffmann-La Roche
Phase 1/2
498
Leicester, London
2019-08-13
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
CellCentric Ltd.
Phase 1/2
250
Sutton, Bebington, Bristol, Cardiff, Derby, Edinburgh, Glasgow, Leicester
2019-08-09
Active, closed
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
587
Cambridge, Leicester, Liverpool, Maidstone, Manchester
2019-07-02
Recruiting
Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk
NCT04029363Mitral Regurgitation
HighLife SAS
Not applicable
120
Belfast, Brighton, Edinburgh, Leeds, Leicester, London, Oxford
2019-05-28
Active, closed
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
NCT03802799Fragile X Syndrome
Zynerba Pharmaceuticals, Inc.
Phase 2/3
476
Leicester, Edinburgh, Manchester
2018-11-09
Recruiting
A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal Nerves
NCT05110989Post Operative Pain
AtriCure, Inc.
Observational
5,000
Leicester
2018-06-29
Active, closed
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT03533283Non-Hodgkins Lymphoma
Hoffmann-La Roche
Phase 1/2
211
Leicester, London, Newcastle upon Tyne
2018-05-08
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
797
Leicester, Metropolitan Borough of Wirral, London, Sutton, Nottingham, Birmingham, Newcastle upon Tyne, Plymouth
2018-04-24
Active, closed
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
NCT03330847Metastatic Triple Negative Breast Cancer
AstraZeneca
Phase 2
273
Aberdeen, Bristol, Cardiff, Durham, Edinburgh, Leicester, London, Manchester
2018-03-07
Recruiting
A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.
NCT03320304Treatment Resistant Depression
LivaNova
Observational
500
Leicester, London, Newcastle upon Tyne, Wells
2017-12-14
Active, closed
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03164616Non Small Cell Lung Cancer NSCLC
AstraZeneca
Phase 3
1,186
Leicester, London, Manchester
2017-06-01
Active, closed
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
NCT02970318Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
310
Birmingham, Cambridge, Canterbury, Leicester, London, Maidstone, Manchester, Southampton
2017-02-02
Active, closed
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
NCT02477696Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
533
Birmingham, Bournemouth, Cambridge, Cardiff, Greater London, Hull, Leeds, Leicester
2015-07-28
Active, closed
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
NCT02503423Solid Tumors, Lymphoma
Taiho Oncology, Inc.
Phase 1/2
253
Leicester, Southampton, Oxford, Sutton, Birmingham, Glasgow, London, Manchester
2015-07-14
Active, closed
Micra Transcatheter Pacing System Post-Approval Registry
NCT02536118Bradycardia
Medtronic
Observational
3,100
Birmingham, Bristol, Leeds, Leicester, Liverpool, London, Manchester, Middlesbrough
2015-07
Active, closed
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
NCT02475681Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
535
Bournemouth, Cambridge, Leeds, Leicester, London, Plymouth, Southampton, Truro
2015-06-26
Active, closed
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
NCT02213926Mantle Cell Lymphoma (MCL)
Acerta Pharma BV
Phase 2
124
Cardiff, Leeds, Leicester, Nottingham, Oxford, Plymouth, Southampton
2015-03-02
Active, closed
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
NCT02362503HIV Infections
ViiV Healthcare
Phase 3
371
Bournemouth, Leicester, London
2015-02-23
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Bristol, London, Leicester, Stanmore, Oxford, Sheffield, Newcastle upon Tyne, Birmingham
2015-01-20
Rows per page Showing 101–200 of 206
Previous 1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/leicester?page=2

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.